Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy

Abbas Bagheri, Mohammad Abbaszadeh, Shahin Yazdani, Abbas Bagheri, Mohammad Abbaszadeh, Shahin Yazdani

Abstract

Purpose: To evaluate the effect of orbital steroid injections in patients with active thyroid ophthalmopathy resistant to or dependent on systemic steroids, or with complications related to systemic steroid use.

Methods: This prospective non-comparative case series includes 31 eyes of 17 patients with active thyroid ophthalmopathy and clinical activity score (CAS) of 3 or more, without compressive optic neuropathy or overt exposure keratopathy. All subjects had a history of previous systemic steroid use (with steroid resistance or dependence) or had developed complications related to steroids. A combination of steroids including triamcinolone acetonide 20 mg and dexamethasone 4 mg was injected in the upper and lower retroseptal orbital spaces three or four times at one-month intervals. The patients were examined periodically after each injection and at least three months after the last injection.

Results: Mean pre-injection CAS was 5.2 ± 1.3 which was improved to 1.6 ± 1 after the fourth injection (P < 0.001). Upper and lower lid retraction improved in 100% and 68.2% of the affected eyes, respectively. Strabismus completely resolved in one of five affected patients and the most significant improvement was observed in supraduction. Mean improvement in exophthalmos was 1.2 ± 1.1 mm. Visual acuity did not significantly change after the injections. Eyelid ecchymosis and/or subconjunctival hemorrhage was observed in 7.1% and intraocular pressure rise occurred in 8.8% of eyes.

Conclusion: Orbital steroid injections can be used for the treatment of active thyroid ophthalmopathy when the patient is resistant to or dependent on systemic steroids or has developed complications of systemic steroids.

Keywords: Lid Retraction; Orbital Inflammation; Proptosis; Steroid Injection; Graves.

Conflict of interest statement

There are no conflicts of interest.

Copyright © 2020 Bagheri et al.

Figures

Figure 1
Figure 1
Bar diagram of changes in mean clinical activity score (CAS) before the injections up to the final examination.
Figure 2
Figure 2
Line diagram of changes in mean lids retraction before the injections up to the last examination.
Figure 3
Figure 3
Bar diagram of changes in mean amount of proptosis before the injections up to the final examination.
Figure 4
Figure 4
Two representative patients before injections (A,C) and at final examinations (B,D).

References

    1. Wang Y., Smith T. J. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Investigative Ophthalmology & Visual Science. 2014;55(3):1735–1748. doi: 10.1167/iovs.14-14002.
    1. Bahn R. S. Emerging pharmacotherapy for treatment of Graves' disease. Expert Review of Clinical Pharmacology. 2012;5(6):605–607. doi: 10.1586/ecp.12.54.
    1. Bartalena L., Baldeschi L., Boboridis K., Eckstein A., Kahaly G. J., Marcocci C., Perros P., Salvi M., Wiersinga W. M. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. European Thyroid Journal. 2016;5(1):9–26. doi: 10.1159/000443828.
    1. Menconi F., Profilo M. A., Leo M., Sisti E., Altea M. A., Rocchi R., Latrofa F., Nardi M., Vitti P., Marcocci C., Marinò M. Spontaneous improvement of untreated mild Graves' ophthalmopathy: rundle's curve revisited. Thyroid. 2014;24(1):60–66. doi: 10.1089/thy.2013.0240.
    1. Wiersinga WM. Graves' orbitopathy: management of difficult cases. Indian J Endocrinol Metab. 2012:16–S150.
    1. Perumal B., Meyer D. R. Treatment of Severe Thyroid Eye Disease. Ophthalmic Plastic & Reconstructive Surgery. 2015;31(2):127–131. doi: 10.1097/IOP.0000000000000216.
    1. Marcocci C., Bartalena L., Tanda M. L., Manetti L., Dell'Unto E., Rocchi R., Barbesino G., Mazzi B., Bartolomei M. P., Lepri P., Cartei F., Nardi M., Pinchera A. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. The Journal of Clinical Endocrinology & Metabolism. 2001;86(8):3562–3567. doi: 10.1210/jc.86.8.3562.
    1. Stiebel-Kalish H., Robenshtok E., Hasanreisoglu M., Ezrachi D., Shimon I., Leibovici L. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. The Journal of Clinical Endocrinology & Metabolism. 2009;94(8):2708–2716. doi: 10.1210/jc.2009-0376.
    1. Hamed-Azzam S., Mukari A., Feldman I., Saliba W., Jabaly-Habib H., Briscoe D. Fornix triamcinolone injection for thyroid orbitopathy. Graefe's Archive for Clinical and Experimental Ophthalmology. 2015;253(5):811–816. doi: 10.1007/s00417-015-2957-7.
    1. Chee E., Chee S. Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series. Eye. 2008;22(2):311–315. doi: 10.1038/sj.eye.6702933.
    1. Xu D., Liu Y., Xu H., Li H. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy. Canadian Journal of Ophthalmology. 2012;47(1):34–41. doi: 10.1016/j.jcjo.2011.12.005.
    1. Lee S. J., Rim T. H. T., Jang S. Y., Kim C. Y., Shin D. Y., Lee E. J., Lee S. Y., Yoon J. S. Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections. Graefe's Archive for Clinical and Experimental Ophthalmology. 2013;251(1):261–270. doi: 10.1007/s00417-012-2153-y.
    1. Pooniathalang A., Preechawat P., Charoenkul W., Tangtrakul P. Tangtrakul P. Retrobulbar injection of triamcinolone in thyroid associated orbithopathy. J Med Assoc Thai. 345–349: 88; 2005. Retrobulbar injection of triamcinolone in thyroid associated orbithopathy. J Med Assoc Thai; pp. 88–345.
    1. Ebner R., Devoto M. H., Weil D., Bordaberry M., Mir C., Martinez H., Bonelli L., Niepomniszcze H. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. British Journal of Ophthalmology. 2004;88(11):1380–1386. doi: 10.1136/bjo.2004.046193.
    1. Jung B. Y., Kim Y. D. The Results of Periocular Injections of Triamcinolone for Thyroid Orbitopathy. Journal of the Korean Ophthalmological Society. 2007;48(9):1163. doi: 10.3341/jkos.2007.48.9.1163.
    1. Khafagy A. Repeated retrobulbar injections of triamcinolone acetonide for thyroid orbitopathy. Med J Cairo Univ. 195–198: 79; 2011.
    1. Bordaberry M., Marques D. L., Pereira-Lima J. C., Marcon I. M., Schmid H. Repeated peribulbar injections of triamcinolone acetonide: A successful and safe treatment for moderate to severe Graves' ophthalmopathy. Acta Ophthalmologica. 2009;87(1):58–64. doi: 10.1111/j.1755-3768.2008.01171.x.
    1. Jacqueline R Carrasco V. S. Effect of Intraorbital Steroid Injections on Intraocular Pressure in Thyroid Eye Disease. Journal of Thyroid Disorders & Therapy. 2014;04(01) doi: 10.4172/2167-7948.1000173.
    1. Goldberg R. A. Orbital steroid injections. British Journal of Ophthalmology. 2004;88(11):1359–1360. doi: 10.1136/bjo.2004.051755.
    1. Alkawas A. A., Hussein A. M., Shahien E. A. Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Clinical & Experimental Ophthalmology. 2010;38(7):692–697. doi: 10.1111/j.1442-9071.2010.02332.x.
    1. Mourits M. P., Prummel M. F., Wiersinga W. M., Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clinical Endocrinology. 1997;47(1):9–14. doi: 10.1046/j.1365-2265.1997.2331047.x.
    1. Dolman P. J., Rootman J. VISA classification for Graves orbitopathy. Ophthalmic Plastic & Reconstructive Surgery. 2006;22(5):319–324. doi: 10.1097/01.iop.0000235499.34867.85.
    1. Werner S. C. Classification of the eye changes of Graves' disease. American Journal of Ophthalmology. 1969;68(4):646–648. doi: 10.1016/0002-9394(69)91246-x.
    1. Barrio-Barrio J., Sabater A. L., Bonet-Farriol E., Velázquez-Villoria Á., Galofré J. C. Graves' ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. Journal of Ophthalmology. 2015;2015 doi: 10.1155/2015/249125.249125
    1. Zang S., Ponto KA., Kahaly GJ. Intravenous glucocorticoids for Graves' orbithopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011:96–320.
    1. Chundury R. V., Weber A. C., Perry J. D. Orbital Radiation Therapy in Thyroid Eye Disease. Ophthalmic Plastic & Reconstructive Surgery. 2016;32(2):83–89. doi: 10.1097/IOP.0000000000000544.
    1. Kim J. W., Han S. H., Son B. J., Rim T. H., Keum K. C., Yoon J. S. Efficacy of combined orbital radiation and systemic steroids in the management of Graves’ orbitopathy. Graefe's Archive for Clinical and Experimental Ophthalmology. 2016;254(5):991–998. doi: 10.1007/s00417-016-3280-7.
    1. Li Y., Luo Y., He W., Li P., Wang F. Clinical outcomes of graves’ ophthalmopathy treated with intensity modulated radiation therapy. Journal of Radiation Oncology. 2017;12(1) doi: 10.1186/s13014-017-0908-7.
    1. Strianese Diego, Iuliano Adriana, Ferrara Mariantonia, Comune Chiara, Baronissi Immacolata, Napolitano Pasquale, D’Alessandro Alessia, Grassi Piergiacomo, Bonavolontà Giulio, Bonavolontà Paola, Sinisi Antonio, Tranfa Fausto. Methotrexate for the Treatment of Thyroid Eye Disease. Journal of Ophthalmology. 2014;2014 doi: 10.1155/2014/128903.128903
    1. TANIKAWA T., OKADA Y., TANAKA Y. Intravenous Cyclophosphamide Pulse Therapy Is Effective for Refractory Graves' Ophthalmopathy. Journal of UOEH. 2006;28(2):185–191. doi: 10.7888/juoeh.28.185.
    1. Chalvatzis N. T., Tzamalis A. K., Kalantzis G. K., El-Hindy N., Dimitrakos S. A., Potts M. J. Safety and Efficacy of Combined Immunosuppression and Orbital Radiotherapy in Thyroid-Related Restrictive Myopathy: Two-Center Experience. European Journal of Ophthalmology. 2018;24(6):953–959. doi: 10.5301/ejo.5000463.
    1. Stan M. N., Garrity J. A., Leon B. G. C., Prabin T., Bradley E. A., Bahn R. S. Randomized controlled trial of rituximab in patients with graves' orbitopathy. The Journal of Clinical Endocrinology & Metabolism. 2015;100(2):432–441. doi: 10.1210/jc.2014-2572.
    1. Ben Simon G. J., Syed H., Douglas R., Schwartz R., Goldberg R. A., McCann J. D. Clinical manifestations and treatment outcome of optic neuropathy in thyroid-related orbitopathy. Ophthalmic Surgery, Lasers & Imaging Retina. 2006;37(4):284–290. doi: 10.3928/15428877-20060701-04.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera